Advanced Search

Study Preview



Study Title and Description

Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia.
Author Maciejko JJ., Brazg R., Shah A., Patil S., Rubenfire M.
Country Department of Medicine, Sinai Hospital, Detroit, Mich.
Year 1994
Numbers Pubmed ID: 7804477

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 1994
  • Comments Comments (
    0
    ) |
Country of Publication United States
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
Was the study blinded? double blind
  • Comments Comments (
    0
    ) |
Study diet type Unspecified
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 27
  • Comments Comments (
    0
    ) |
Is there a run-in period? Yes
  • Comments Comments (
    0
    ) |
Is there a washout period? No
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years 55
  • Comments Comments (
    0
    ) |
Study population, age range in years 36-69
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 -
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 -
  • Comments Comments (
    0
    ) |
Baseline health status Hyperlipidemia/hypercholesterolemia
  • Comments Comments (
    0
    ) |
Gender (% male) ~63
  • Comments Comments (
    0
    ) |
Fiber 1-type Psyllium Hydrophilic Mucilloid (Metamucil)
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) 6.5
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 6 weeks
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Fiber 2-type -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 3-type -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 4-type -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? Inert bulk fiber purified from microcrystalline cellulose
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 6 weeks
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Powder
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.